** H.C. Wainwright starts coverage on biotech firm Virax Biolabs VRAX.O with a "buy" rating and $3 PT, implying a more than twofold upside to stock's last close
** VRAX has an "attractive market opportunity" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a "hundreds of millions of dollars" market, says brokerage
** PAIS refers to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues
** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says
** The test shows promise in evaluating immune status in chronic conditions, with "significant changes" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - H.C. Wainwright
** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。